Sangamo Therapeutics explores strategic alternatives with Raymond James
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders
June 8, 2026 8:05 AM EDTRICHMOND, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that, after extensive consideration of the companys pipeline and financial resources, it has retained Raymond James as its financial advisor to assist in evaluating a full range of strategic alternatives to advance its promising pipeline and to maximize value for all stakeholders.
With our best-in-class BLA-ready Fabry gene therapy program, differentiated zinc finger epigenetic regulation and capsid delivery platforms, and innovative MINT platform for large-scale genomic engineering, we have made... More
